Zoetis, Inc. Stock Plummets to New 52-Week Low of $111.34

Zoetis, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 111.34 as of May 5, 2026. This decline marks a significant downturn for the stock, which has experienced a 37.07% drop over the past year, contrasting sharply with the S&P 500's performance of 28.47% during the same period. The company's market capitalization stands at USD 53,244 million, categorizing it as a large-cap entity. Despite the recent price decline, Zoetis maintains a price-to-earnings (P/E) ratio of 20.00, indicating a moderate valuation relative to its earnings. The stock also offers a dividend yield of 1.71%, reflecting its commitment to returning value to shareholders. Financially, Zoetis demonstrates strong management efficiency, highlighted by a return on equity (ROE) of 80.42% and a robust return on capital employed (ROCE) of 33.61%. The company has shown resilience with a low debt-to-EBITDA ratio of 1.22, suggesting a strong capacity to service its debt obligations. Despite the recent challenges, Zoetis has reported positive results for the last six consecutive quarters, showcasing its operational strength in a competitive market.